Over the past three decades, we have witnessed the progression of small molecule
chemical probes designed to inhibit the catalytic active site of histone deacetylase (HDAC) …

Alzheimer's disease (AD) and Down syndrome (DS) share a common therapeutic target, the
dual-specificity, tyrosine phosphorylation activated kinase 1A (DYRK1A). Abnormally active …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by Aβ deposition,
tauopathy, neuroinflammation, and impaired cognition. The recent identification of …

Multitarget ligands (MTLs) have emerged as an interesting alternative for addressing
complex multifactorial pathologies such as neurodegenerative diseases. However, a …

The prevalence of Alzheimer's disease (AD) and its associated economic and societal
burdens are on the rise, but there are no curative treatments for AD. Interestingly, this …

Malignant tumors and central nervous system (CNS) disorders are intricately linked to a
process known as" aberrant cell cycle re-entry," which plays a critical role in the progression …

Cancers and neurological disorders are two major types of diseases in humans. We
developed the concept called the “Aberrant Cell Cycle Disease (ACCD)” due to the …

Summary Protein phosphatase 2A (PP2A) is an essential Ser/Thr phosphatase. The PP2A
holoenzyme complex comprises a scaffolding (A), regulatory (B), and catalytic (C) subunit …

Aim: This study aims to investigate the passive diffusion of protein kinase inhibitors through
the blood–brain barrier (BBB) and to develop a model for their permeability prediction …

Neurodegenerative movement disorders represent a growing global health challenge. The
most notable of these include amyotrophic lateral sclerosis (ALS), Huntington's disease …